首页> 外文期刊>Internal medicine journal >Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management.
【24h】

Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management.

机译:甲状腺相关性眼病:分类,自然病史和治疗的实用指南。

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Thyroid-associated ophthalmopathy (TAO) is an autoimmune disorder that can be divided into three clinical subtypes: congestive, myopathic and mixed ophthalmopathy. It is probably caused by immune cross-reactivity between orbital and thyroid antigens. The best candidate antigens are the thyrotropin receptor and the novel protein, G2s, which is now identified as a fragment of the winged helix transcription factor, FOXP1. The relationship between radioiodine therapy and TAO is controversial, with two randomised controlled trials showing a transient worsening of the eye disease after treatment. The diagnosis of TAO is a clinical one, based on the presence of specific symptoms and signs. Orbital imaging, preferably magnetic resonance imaging, is useful when the diagnosis is in doubt and in patients with suspected optic neuropathy who may benefit from early intervention. Despite their lack of specificity, orbital antibodies may add weight to the diagnosis and may potentially be a useful tool in classifying the different subtypes of TAO and in monitoring disease activity. While antibodies against G2s and the thyrotropin receptor are seen in all subtypes, those against Fp and collagen XIII may be associated with the myopathic and congestive subtypes, respectively, where Fp is the flavoprotein subunit of the mitochondrial enzyme, succinate dehydrogenase. In most patients, TAO is self-limiting and no specific treatment is required. When treatment is indicated, glucocorticoids are the mainstay of therapy. Orbital radiotherapy improves the efficacy of glucocorticoids, but is probably less beneficial as monotherapy. Orbital surgery is best reserved for patients with 'burnt out' inactive disease, but urgent orbital decompression may be required for optic neuropathy. The severity and clinical activity of TAO are important in determining the need for specific treatment and the likelihood of success with medical therapy, respectively. (Intern Med J 2004; 34: 482-491)
机译:摘要甲状腺相关性眼病(TAO)是一种自身免疫性疾病,可分为三种临床亚型:充血性,肌病性和混合性眼病。它可能是由眼眶和甲状腺抗原之间的免疫交叉反应引起的。最佳候选抗原是促甲状腺激素受体和新型蛋白质G2s,现在已将其鉴定为有翼螺旋转录因子FOXP1的片段。放射性碘疗法与TAO的关系存在争议,两项随机对照试验显示治疗后眼部疾病暂时恶化。基于特定症状和体征的存在,TAO的诊断是临床诊断。当对诊断有疑问时,以及在怀疑患有视神经病且可能会从早期干预中受益的患者中,眼眶成像(最好是磁共振成像)很有用。尽管缺乏特异性,但轨道抗体可能会增加诊断的重量,并且可能是分类TAO不同亚型和监测疾病活动的有用工具。虽然在所有亚型中都发现了针对G2s和促甲状腺激素受体的抗体,但针对Fp和胶原XIII的抗体可能分别与肌病和充血性亚型相关,其中Fp是线粒体酶(琥珀酸脱氢酶)的黄素蛋白亚基。在大多数患者中,TAO是自限性的,不需要特殊治疗。当需要治疗时,糖皮质激素是治疗的主体。轨道放疗可提高糖皮质激素的疗效,但单药治疗的益处可能较小。眼眶手术最适合患有“精疲力竭”的非活动性疾病的患者,但视神经病变可能需要紧急眼眶减压。 TAO的严重性和临床活性分别对确定具体治疗的需要和药物治疗成功的可能性至关重要。 (实习生J 2004; 34:482-491)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号